Hematology/Oncology and Bone Marrow Transplantation

Chief, Division of Pediatric Hematology/Oncology
Professor of Pediatrics, University of Pittsburgh School of Medicine


Division of Pediatric Hematology/Oncology
Children's Hospital of Pittsburgh
3705 Fifth Ave.
Pittsburgh, PA 15213

412-692-5055
412-692-7693 Fax
kim.ritchey@chp.edu
Patient Appointment Information

Medical School:

1972 University of Cincinnati Medical College

Residency:

1975 Johns Hopkins Hospital, Baltimore, MD

Fellowship:

1980 Yale University School of Medicine, New Haven, CT

• Children's Oncology Group
• American Society of Pediatric Hematology/Oncology
• American Society of Clinical Oncology

• National Board of Medical Examiners
• American Board of Pediatrics, Sub-Board of Pediatric Hematology/Oncology

• 2005 Best Doctors in America
• 2005 "Top Doctors" in Pittsburgh
• 2005 Professional Research Consultants (PRC) Four Star Customer Service Award

• Stress Management for Families of Children with Cancer
• Chronic Stress and Proinflammatory Cytokine Regulation

Treatment for childhood cancer has come a long way in the last 50 years. A. Kim Ritchey, MD, is doing his part to ensure that Children's Hospital of Pittsburgh maintains its position as a leader of that progress. Dr. Ritchey is chief of the Division of Pediatric Hematology/Oncology at Children's Hospital, professor of pediatrics at the University of Pittsburgh School of Medicine and one of the elected board members of the American Society of Pediatric Hematology/Oncology.

Dr. Ritchey also is the principal investigator for the Children's Oncology Group (COG), which is now the only pediatric clinical trials organization funded by the U.S. National Cancer Institute. In his position, he is responsible for overseeing clinical research trials in different types of childhood malignancy. The COG currently has more than 75 active clinical research trials for children with cancer. Children's is one of only 20 select institutions within the COG that has approval to perform experimental studies with new drugs and treatments for children with cancer, also known as Phase I studies.

In the research studies he is overseeing at Children's, Dr. Ritchey is helping to increase the understanding of why some children are difficult to cure- for example, why some tumor cells have the ability to rapidly develop resistance to chemotherapy while others are responsive to therapy.

Dr. Ritchey is experienced in central nervous system leukemia and led a national clinical research trial in this area, which resulted in some of the best therapy published to date. He also is knowledgeable in hematologic disorders and has participated in clinical trials in idiopathic thrombocytopenic purpura1, anemia of malignancy, and sickle cell disease. His clinical interests include general cancer management, coagulation and bleeding disorders.

1 "Idiopathic" means that the cause is unknown. "Thrombocytopenic" means the blood doesn't have enough platelets. "Purpura" means a person has excessive bruising. In people with ITP, all of the blood cells are normal except for the blood platelets. A person with too few platelets bruises easily and bleeds for a long time after being injured. Tiny red dots on the skin, called petechiae, might also appear. When the platelet count is very low, the person with ITP might have nosebleeds that are hard to stop, or might have bleeding in the intestines.